메디채널

주메뉴 바로가기
본문 바로가기

기상청 제공

닫기

라이프

Empowering Modern Mothers: Ddrops® Supports the Health of Children and Families

KUALA LUMPUR, Malaysia, Dec. 10, 2025 -- Ddrops® participated in the Dear Mom x Ddrops® event, hosted by Innity Group, at IPC Shopping Centre, Malaysia, to engage with modern mothers and emphasize the importance of maternal support, emotional well-being, and self-care. Reflecting the realities of motherhood today, the event featured interactive zones, including the Self-Love Consultation Booth, Sponsored Brands Experience Zone, Dear Me Reflection Wall, and Creator Photo Zone, offering mothers a space to connect, share experiences, and rediscover themselves beyond caregiving. &n
- 김갑성 기자
- 2025-12-10 10:30
Beijing 101 Launches Tri-Action Scalp Revival Treatment, The Ultimate Multi-Technology Scalp Rejuvenation Solution

SINGAPORE, Dec. 10, 2025 -- Beijing 101 Hair Consultants is thrilled to announce the launch of its latest treatment innovation – the Tri-Action Scalp Revival Treatment – a systematic, multi-technology hair and scalp treatment that cleanses, nourishes, and rejuvenates the scalp through a defined sequence of professionally guided steps. This new treatment reinforces Beijing 101's pledge to provide effective, state-of-the-art treatment solutions for hair and scalp issues, with Traditional Chinese Medicine (TCM) principles. Developed with precision and a clear methodology, the Tri-
- 김갑성 기자
- 2025-12-10 10:00
MALAYSIA UNVEILS FIRST FLAGSHIP MEDICAL TOURISM HOSPITAL AWARD WINNER TO DRIVE GLOBAL ECONOMY COMPETITIVENESS

KUALA LUMPUR, Malaysia, Dec. 10, 2025 -- Malaysia Healthcare Travel Council (MHTC) marked a major milestone in its medical tourism journey today with the announcement of the Winner of the Flagship Medical Tourism Hospital (FMTH) Programme, an initiative initiated and led by the Malaysia Healthcare Travel Council (MHTC) to elevate Malaysia's position as the preferred medical tourism destination in the world. The announcement was made during the FMTH 2025 Award Ceremony, held at M Resort & Hotel Kuala Lumpur. The event was officiated by YB Datuk Seri Dr. Dzulkef
- 김갑성 기자
- 2025-12-10 09:40
D3 Bio Secures $108 Million in Series B Financing to Advance Global Clinical Programs

SHANGHAI, Dec. 10, 2025 -- D3 Bio, a global clinical-stage biotechnology company focused on the discovery and development of innovative oncology therapeutics, announced the completion of a $108 million Series B financing round. The funding round was backed by a distinguished group of investors, including IDG Capital and SongQing Capital. Existing investors — WuXi AppTec's Corporate Venture Fund, Temasek, HSG, MPCi, and Medicxi — also contributed to the round. The robust involvement from both new and current investors highlights widespread confidence in D3 Bio's in
- 김갑성 기자
- 2025-12-10 09:30
Innovent Announces First Participant Dosed in a Phase 1 Clinical Trial of IBI3011, a Recombinant Anti-Human Interleukin 1 Receptor Accessory Protein Monoclonal Antibody

[ 메디채널 김갑성 기자 ] SAN FRANCISCO and SUZHOU, China, Dec. 10, 2025 -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune, ophthalmology and other major disease areas, announced that the first participant has been successfully dosed in a Phase 1 clinical trial of IBI3011, an anti-human Interleukin 1 receptor accessory protein (IL-1RAP) monoclonal antibody developed by Innovent. This study is a single ascending
- 김갑성 기자
- 2025-12-10 08:26
Lee's Pharmaceutical Holdings Limited Acquires Staccato® One Breath Technology® Platform and Assets, Driving Pipeline Expansion and Advancing Global Partnership with UCB Through Acquired Rights

Acquisition of Staccato® One Breath Technology®, a proprietary platform technology with broad therapeutic potential Synergistic and complementary to Lee's Pharm's existing products pipeline, and Acquisition of rights as licensor and manufacturer of Staccato® alprazolam under a global partnership with UCB HONG KONG, Dec. 10, 2025 -- Nova Pneuma Inc. ("NPI"), the Delaware incorporated and wholly owned subsidiary of Lee's Pharmaceutical Holdings Limited (0950.HK) ("Lee's Pharm" or the "Company"), announced today the assets acquisi
- 김갑성 기자
- 2025-12-10 08:00
PhyxUp Health Leads Innovation in US Rehabilitation Market with AI-Powered Remote Therapeutic Monitoring(RTM), Launches $1M Seed Funding Round

SAN FRANCISCO, Dec. 10, 2025 -- PhyxUp Health, an AI-driven Remote Therapeutic Monitoring (RTM) platform founded by a former physical therapist and Harvard graduate, is transforming how rehabilitation clinics operate throughout the United States. Built as a next-generation patient management and engagement solution, PhyxUp enables clinics to remotely monitor patient progress, increase therapy adherence, and streamline communication beyond the clinic walls. The platform incorporates automated documentation and integrated RTM billing, ensuring clean reimbursement workflows that help outpatient
- 김갑성 기자
- 2025-12-10 00:00
BestQool Launches Christmas Campaign Crossing Into 2026 Before the Next Wave of New Product Updates

NEW YORK, Dec. 9, 2025 -- BestQool is now giving a holiday offer to help people smoothly move into 2026 as the year comes to an end and the holidays approach. From December 10, 2025, to January 4, 2026, customers can get 15% off all BestQool light therapy products on the BestQool official website. Also, from December 24, 2025, to January 6, 2026, customers who want red light devices that look like belts or yoga mats can get up to 23% off Redot series products when they buy them from the BestQool Amazon store. This Christmas, give the gift of health. The holidays are fun, but th
- 김갑성 기자
- 2025-12-09 23:56
메나리니 그룹, 2025 샌안토니오 유방암 심포지엄에서 엘라세스트란트(ORSERDU)®의 ER+, HER2- 전이성 유방암(mBC) 환자 대상 2상 병용 요법 데이터 발표

또한, 광범위한 엘라세스트란트 임상 개발 프로그램 업데이트는 전이성 유방암과 초기 단계 유방암 모두에서 병용 요법의 기반이 되는 내분비 치료로서의 잠재력을 강화한다. 이탈리아 피렌체 및 뉴욕, 2025년 12월 9일 -- 선도적인 글로벌 제약 및 진단 기업인 메나리니 그룹(Menarini Group, 이하 '메나리니')과 스템라인 테라퓨틱스(Stemline Therapeutics, Inc. , 이하 '스템라인')가 에스트로겐 수용체 양성(ER+), HER2 음성(HER2-) 국소 진행성 또는 전이성 유방암(mBC) 환자를 대상으로 한 2상 ELEVATE 연구에서 두 가지 병용 치료군의 의미 있는 무진행 생존기간 중앙값(mPFS) 최신 결과를 발표한다. 스템라인 테라퓨틱스는 메나리니 그룹의 전액 출자 자회사로 암 환자에게 혁신적인 종양 치료를 제공하는 데 주력한다. ELEVATE 연구는 ER+/HER2- mBC에서 관찰되는 다양한 내성 기전을 극복해 환자 치료 성과를 향상시키는 것을 목표로, 경구-경구 병용 요법의 안전성과 유효성을 평가하도록 설계된 연구다. 관련 데이터는 12월 9~12일 열리는 2025년 샌안토니오 유방
- 김갑성 기자
- 2025-12-09 22:49
Neurophet Introduced Use Cases of Its AI-based Brain Imaging Analysis Solutions at the SEACURE Symposium Hosted by Nanyang Technological University in Singapore

Introduced brain-imaging analysis products, including Neurophet AQUA AD, which enables monitoring of adverse effects related to Alzheimer's disease treatments Highlighted clinical value of Neurophet AQUA AD…To accelerate efforts across healthcare institutions in Southeast Asia SEOUL, South Korea, Dec. 9, 2025 -- Neurophet (Co-CEOs Jake Junkil Been and Donghyeon Kim), an artificial intelligence (AI) solution company for brain disorders diagnosis and treatment, announced on 9th that it participated in a symposium held on the 28th of last month (local time). The event was h
- 김갑성 기자
- 2025-12-09 22:00

이전

11 12 13 14 15 16 17 18 19 20

많이 본 기사

최근기사

2026-01-01_THU

발행인 : 최희정 | 편집인 : 김갑성 |
등록번호: 서울특별시 아53302 | 등록일 2020-09-25 | 전화번호 02-565-7119 |
주소 : 서울특별시 강남구 영동대로 602, 6층 E115 (삼성동)
Copyright @메디채널 Corp. All rights reserved.

UPDATE: 2026년 01월 01일 22시 40분